Minerva Neurosciences Stock Forecast, Price & News

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NERV shares have decreased by 38.8% and is now trading at $3.89.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Minerva Neurosciences or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings data on Monday, November, 2nd. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.03.
View Minerva Neurosciences' earnings history.

6 Wall Street analysts have issued twelve-month price objectives for Minerva Neurosciences' shares. Their forecasts range from $2.00 to $10.00. On average, they anticipate Minerva Neurosciences' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price.
View analysts' price targets for Minerva Neurosciences.

Minerva Neurosciences saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,510,000 shares, a drop of 14.0% from the October 31st total of 2,920,000 shares. Based on an average daily trading volume, of 520,100 shares, the short-interest ratio is presently 4.8 days. Approximately 7.2% of the company's stock are short sold.
View Minerva Neurosciences' Short Interest.

Some companies that are related to Minerva Neurosciences include BioSpecifics Technologies (BSTC), Nabriva Therapeutics (NBRV), Collegium Pharmaceutical (COLL), Basilea Pharmaceutica (BPMUF), IVERIC bio (ISEE), Mirum Pharmaceuticals (MIRM), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Chinook Therapeutics (KDNY), Geron (GERN), Odonate Therapeutics (ODT), Relmada Therapeutics (RLMD), Atreca (BCEL), Ardelyx (ARDX) and Dynavax Technologies (DVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.92%), Acadian Asset Management LLC (4.00%), State Street Corp (1.43%), Sei Investments Co. (0.55%), Arrowstreet Capital Limited Partnership (0.49%) and AQR Capital Management LLC (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle.
View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, AQR Capital Management LLC, BlackRock Inc., Cubist Systematic Strategies LLC, and JPMorgan Chase & Co.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences.

NERV stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Sei Investments Co., State Street Corp, AJO LP, ExodusPoint Capital Management LP, Sanders Morris Harris LLC, BNP Paribas Arbitrage SA, and California State Teachers Retirement System. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, Heek G Jan Van, and William F Doyle.
View insider buying and selling activity for Minerva Neurosciences.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NERV stock can currently be purchased for approximately $3.89.

Minerva Neurosciences has a market capitalization of $166.00 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]